We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The lack of transparency regarding the phosphate content of drugs.
- Authors
Christensen, Kenneth Maersk; Skjøt-Arkil, Helene; Kjeldsen, Lene Juel; Kampmann, Jan Dominik
- Abstract
If phosphate intake could be reduced by 428 mg daily using alternative drugs, the patient will have the opportunity to increase the intake of protein-containing foods, which is recommended in dialysis treatment. Hyperphosphatemia is a risk factor for cardiovascular disease and mineral bone disease, especially in patients treated with hemodialysis [[1]]. The traditional treatment of hyperphosphatemia in dialysis patients consists of dietary advice, treatment with phosphate binders to reduce the absorption of phosphate and intensifying dialysis treatment [[2]].
- Subjects
PHOSPHATES
- Publication
International Journal of Clinical Pharmacy, 2023, Vol 45, Issue 4, p1019
- ISSN
2210-7703
- Publication type
Article
- DOI
10.1007/s11096-023-01594-w